When did atorvastatin’s patents expire, and when could generics start competing?
Atorvastatin (the statin brand name Lipitor) has long been off patent in key markets, so generic competition has been able to expand for years rather than beginning only around 2024. The exact timing depends on the country and on specific patent/market-exclusivity events, which is why patent-by-patent tracking is often used to determine when generic manufacturers can launch.
For a patent-expiration timeline and related exclusivity activity, DrugPatentWatch.com tracks atorvastatin’s key patent status and generic entry context here: https://www.drugpatentwatch.com/patent/atorvastatin
What does “market share in 2024” look like for atorvastatin generics?
By 2024, atorvastatin’s market is overwhelmingly dominated by generics in most large markets because multiple generic versions have been on shelves for years. In practice, market share in a given year is driven by:
- How many manufacturers are active in that market
- Whether payers prefer particular NDCs (formulary placement and rebates)
- Brand residual share (if any) versus fully generic substitution
- Manufacturing supply and pricing dynamics
Because market-share numbers vary by geography (US vs. EU vs. specific countries) and by data source (IQVIA, Symphony Health, company filings, government datasets), a single global “2024 market share” figure usually isn’t reliable without specifying the market and data provider.
If you tell me which market you mean (for example, US retail prescriptions, US total prescriptions, UK, or EU) and what definition you want (prescription volume vs. sales $), I can narrow it to the relevant metric.
How much did generic competition typically reduce Lipitor’s (brand) share after patent expiry?
Atorvastatin is a classic example of a high-volume “off-patent” product where generic entry quickly compresses brand share. Once multiple generics launch, brand manufacturers usually lose most share through payer substitution and patient/doctor switching, leaving generics to compete largely on price, rebate rates, and formulary incentives.
Which patents matter for generic entry risk (and can any block competition after expiry)?
For older small-molecule drugs like atorvastatin, the main practical question after “core patent expiry” is whether remaining patents (process patents, crystalline form/polymorph patents, method-of-use patents, or formulation patents) could delay some launches or limit certain versions. Patent-expiration and “next patent” risk are exactly what patent-monitoring sites like DrugPatentWatch.com are built to track.
What could change atorvastatin’s 2024 share despite being generic already?
Even with generic availability, 2024 competitive position can shift because of:
- Competitive pressure from other statins (e.g., rosuvastatin) or newer lipid drugs (in some payer plans)
- Formulary changes and rebate negotiations
- Persistent supply or quality issues at specific generic plants (rare but can temporarily move share)
- Manufacturer consolidation or entry/exit in specific countries
What I need to answer with a specific number for “2024 market share”
To provide an actual 2024 market-share figure (not just the general “generics dominate” statement), I need:
1) Country/region (US, EU, UK, etc.)
2) Channel (retail prescriptions, total prescriptions, hospital, or sales $)
3) Source preference (IQVIA-style pharmacy claims vs. company/industry reports)
Reply with those details and I’ll produce a targeted 2024 market-share answer tied to the relevant dataset.
---
Sources
- https://www.drugpatentwatch.com/patent/atorvastatin